BVF INC/IL
CIK 1056807 · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.17B
Companies
25
Total Filings
38
Lifetime Open-Market Net
$10.09M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MLTX | Director | 6,599,722 | $18.71 | $123.48M | $0 | 1 | 2026-06-22 |
| XOMAP | 10%+ Owner | 3,545,545 | $24.98 | $88.57M | $0 | 2 | 2026-05-18 |
| OLMA | Director | 2,103,522 | $11.62 | $24.44M | $0 | 1 | 2025-06-13 |
| ELDN | 10%+ Owner | 2,633,679 | $3.40 | $8.95M | $0 | 1 | 2024-10-31 |
| KYMR | Director | 294,632 | $106.16 | $31.28M | $41.50M | 2 | 2024-01-09 |
| Third Harmonic Bio, Inc. (THRD) Delisted | 10%+ Owner | 2,332,638 | $5.38 | $12.55M | $8.79M | 1 | 2022-12-22 |
| CTI BIOPHARMA CORP (CTIC) Delisted | 10%+ Owner | 1,784,461 | $9.09 | $16.22M | $133.00M | 2 | 2022-03-11 |
| CYTK | 2,760,185 | $79.45 | $219.30M | -$77.57M | 1 | 2020-12-11 | |
| Merus N.V. (MRUS) Delisted | 10%+ Owner | 2,200,035 | $90.00 | $198.00M | $17.24M | 1 | 2020-09-17 |
| IDYA | 10%+ Owner | 1,204,981 | $36.16 | $43.57M | $337.0K | 1 | 2020-07-02 |
| Calithera Biosciences, Inc. (CALA) Delisted | 10%+ Owner | 32,927 | $0.00 | $10 | $3.03M | 1 | 2019-11-18 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 2,958,503 | $38.00 | $112.42M | $27.11M | 1 | 2019-11-07 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | 10%+ Owner | 9,654 | $13.60 | $131.3K | $0 | 1 | 2019-02-01 |
| XOMA | 10%+ Owner | 355,527 | $40.17 | $14.28M | $6.28M | 1 | 2018-12-10 |
| XENE | 10%+ Owner | 297,464 | $64.94 | $19.32M | $1.82M | 1 | 2017-06-30 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 3,627,610 | $0.04 | $162.2K | $6.94M | 1 | 2016-12-30 |
| LGND | 10%+ Owner | 2,008,834 | $296.28 | $595.18M | -$303.29M | 4 | 2013-11-29 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | 10%+ Owner | 4,555,829 | — | — | $2.95M | 1 | 2013-08-02 |
| CAPS | 10%+ Owner | 3,522 | $0.25 | $875 | $446.7K | 1 | 2011-07-18 |
| Celera CORP (CRA) Delisted | 10%+ Owner | 38,163,934 | — | — | $167.43M | 2 | 2011-05-17 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | 10%+ Owner | 1,179,292 | $15.50 | $18.28M | -$5.05M | 3 | 2009-08-03 |
| RPRX | 10%+ Owner | 2,740,026 | $59.97 | $164.32M | -$7.29M | 1 | 2009-07-15 |
| RGEN | 10%+ Owner | 5,795,100 | $145.34 | $842.26M | -$14.95M | 1 | 2009-07-08 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 10%+ Owner | 8,308,999 | — | — | $251.8K | 2 | 2008-11-25 |
| AVIGEN INC \DE (AVGN) Delisted | 10%+ Owner | 8,055,315 | — | — | $1.12M | 1 | 2008-11-13 |
Recent Filings · Page 2 of 4
38 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-09-17 | Merus N.V. (MRUS) Delisted | Buy (P) | +1,467,540 | $17.24M | EDGAR |
| 2020-07-02 | IDYA | Buy (P) | +25,310 | $337.0K | EDGAR |
| 2019-11-18 | Calithera Biosciences, Inc. (CALA) Delisted | Buy (P) | +899,416 | $3.03M | EDGAR |
| 2019-11-07 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +6,776,784 | $27.11M | EDGAR |
| 2019-02-01 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Other (J) | −35,000,000 | $0 | EDGAR |
| 2018-12-10 | XOMA | Buy (P) | +427,161 | $6.28M | EDGAR |
| 2018-06-01 | — | Sell (S) | −7,251,573 | -$36.26M | |
| 2018-02-12 | CTI BIOPHARMA CORP (CTIC) Delisted | Mixed | −11,666,669 | $133.00M | EDGAR |
| 2017-06-30 | XENE | Buy (P) | +598,227 | $1.82M | EDGAR |
| 2016-12-30 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Buy (P) | +5,196,807 | $6.94M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.